A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 148 participants.
Also called NCT05930028
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 148 participants
- Registry
-
NCT05930028
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05930028. Randomized; double masking; primary purpose treatment. Start 2023-07-13 (actual); primary completion 2024-09-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia
- Condition
- Essential Hypertension
- Condition
- Primary Hypercholesterolemia
- Intervention (Drug)
- Fimasartan
- Intervention (Drug)
- Ezetimibe/Atorvastatin
- Intervention (Drug)
- Fimasartan Placebo
- Intervention (Drug)
- Ezetimibe/Atorvastatin Placebo
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct05930028- Content hash
a3c59d2f97e300ad25a57b1ffff13695502c1b4552499391f1915a732acc1340